Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Epaminurad. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.79 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.79 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epaminurad SCHEMBL1191044 | 0.98 | SLC22A12 (0.79) | SLC22A12SLC22A6SLC22A8KCNH2POLB | |
| Epaminurad SCHEMBL1191165 | 0.88 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A8KCNH2POLB | |
| Epaminurad SCHEMBL1189980 | 0.87 | SLC22A12 (0.98) | SLC22A12SLC22A6SLC22A8KCNH2POLB | |
| SCHEMBL27101417 | 0.87 | SLC22A12 (0.80) | SLC22A12SLC22A6SLC22A8KCNH2POLB | |
| Epaminurad SCHEMBL1191581 | 0.87 | SLC22A12 (0.98) | SLC22A12SLC22A6SLC22A8KCNH2POLB | |
| Epaminurad SCHEMBL1191045 | 0.87 | SLC22A12 (0.98) | SLC22A12SLC22A6SLC22A8KCNH2POLB | |
| Epaminurad SCHEMBL1190282 | 0.87 | SLC22A12 (0.98) | SLC22A12SLC22A6SLC22A8KCNH2POLB | |
| Epaminurad SCHEMBL1190775 | 0.85 | SLC22A12 (0.89) | SLC22A12SLC22A6SLC22A8KCNH2POLB | |
| SCHEMBL13037469 | 0.84 | SLC22A12 (0.87) | SLC22A12SLC22A6SLC22A8KCNH2POLB | |
| SCHEMBL1190005 | 0.84 | SLC22A12 (0.76) | SLC22A12SLC22A6SLC22A8KCNH2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266989-B1 | HETEROCYCLIC DERIVATIVES | C & C RES LAB (KR) | 2015-09-02 | — | — | EP | claimed |
| US-8394792-B2 | Heterocyclic derivatives | C&C RESEARCH LABORATORIES (KR) | 2013-03-12 | — | — | US | claimed |
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | C&C RESEARCH LABORATORIES (KR) | 2011-02-03 | — | — | US | claimed |
| EP-2266989-A2 | HETEROCYCLIC DERIVATIVES | C&c Research Laboratories (KR) | 2010-12-29 | — | — | EP | claimed |
| EP-2266989-B1 | HETEROCYCLIC DERIVATIVES | C & C RES LAB (KR) | 2015-09-02 | — | — | EP | disclosed |
| US-8394792-B2 | Heterocyclic derivatives | C&C RESEARCH LABORATORIES (KR) | 2013-03-12 | — | — | US | disclosed |
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | C&C RESEARCH LABORATORIES (KR) | 2011-02-03 | — | — | US | disclosed |
| EP-2266989-A2 | HETEROCYCLIC DERIVATIVES | C&c Research Laboratories (KR) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | XDH, NUDT1, UGDH | SLC22A12 692/4885SLC22A6 625/4885SLC22A8 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.